title: Synergistic antitumor effect of β-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells.
abstract: β-Elemene, an anticancer agent, was isolated from the traditional Chinese medicine plant, curcuma aromatica. In this study, we investigated the synergistic antitumor effect of β-elemene and etoposide phosphate (VP-16) in A549 non-small cell lung carcinoma cells. The cells were treated with β-elemene (20 or 50 µg/ml), VP-16 (15 µg/ml) or the combination of both for 24 h. Compared to the treatment with β-elemene or VP-16 alone, an increased antitumor activity was observed with the combination of both, which was mediated by the cleavage of PARP, the up-regulation of Bax, p53 and p21, and the suppression of cyclin D1. These results suggest that the combination of β-elemene and VP-16 may be a promising therapeutic option for lung cancer.
authors: Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang 110001, PR China.
authors: Fan
authors: F
authors: Zhang
authors: Ling
authors: L
authors: Xu
authors: Xiujuan
authors: X
authors: Qu
authors: Mingfang
authors: M
authors: Zhao
authors: Bo
authors: B
authors: Jin
authors: Jian
authors: J
authors: Kang
authors: Yunpeng
authors: Y
authors: Liu
authors: Xuejun
authors: X
authors: Hu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D017209:Apoptosis / Q000187:drug effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism; D059447:Cell Cycle Checkpoints / Q000187:drug effects*; D045744:Cell Line, Tumor; D030024:Curcuma / Q000737:chemistry; D019938:Cyclin D1 / Q000378:metabolism; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000378:metabolism; D005047:Etoposide / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009943:Organophosphorus Compounds / Q000627:therapeutic use / Q000633:toxicity*; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D012717:Sesquiterpenes / Q000627:therapeutic use / Q000633:toxicity*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D050759:Cyclin-Dependent Kinase Inhibitor p21; D009943:Organophosphorus Compounds; D012717:Sesquiterpenes; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; C445979:beta-elemene; D019938:Cyclin D1; C061400:etoposide phosphate; D005047:Etoposide; D011065:Poly(ADP-ribose) Polymerases